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ABSTRACT
ObjeCtive
To determine whether a treatment strategy based on 
structured ultrasound assessment would lead to 
improved outcomes in rheumatoid arthritis, compared 
with a conventional strategy.
Design
Multicentre, open label, two arm, parallel group, 
randomised controlled strategy trial.
setting
Ten rheumatology departments and one specialist centre 
in Norway, from September 2010 to September 2015.
PartiCiPants
238 patients were recruited between September 2010 
and April 2013, of which 230 (141 (61%) female) received 
the allocated intervention and were analysed for the 
primary outcome. The main inclusion criteria were age 
18-75 years, fulfilment of the 2010 American College of 
Rheumatology/European League Against Rheumatism 
classification criteria for rheumatoid arthritis, disease 
modifying anti-rheumatic drug naivety with indication 
for disease modifying drug therapy, and time from first 
patient reported swollen joint less than two years. 
Patients with abnormal kidney or liver function or major 
comorbidities were excluded.
interventiOns
122 patients were randomised to an ultrasound tight 
control strategy targeting clinical and imaging 
remission, and 116 patients were randomised to a 
conventional tight control strategy targeting clinical 
remission. Patients in both arms were treated according 
to the same disease modifying anti-rheumatic drug 
escalation strategy, with 13 visits over two years.
Main OutCOMe Measures
The primary endpoint was the proportion of patients 
with a combination between 16 and 24 months of 
clinical remission, no swollen joints, and non-
progression of radiographic joint damage. Secondary 
outcomes included measures of disease activity, 
radiographic progression, functioning, quality of life, 
and adverse events. All participants who attended at 
least one follow-up visit were included in the full 
analysis set.
results
26 (22%) of the 118 analysed patients in the ultrasound 
tight control arm and 21 (19%) of the 112 analysed patients 
in the clinical tight control arm reached the primary 
endpoint (mean difference 3.3%, 95% confidence interval 
−7.1% to 13.7%). Secondary endpoints (disease activity, 
physical function, and joint damage) were similar 
between the two groups. Six (5%) patients in the 
ultrasound tight control arm and seven (6%) patients in 
the conventional arm had serious adverse events.
COnClusiOns
The systematic use of ultrasound in the follow-up of 
patients with early rheumatoid arthritis treated 
according to current recommendations is not justified 
on the basis of the ARCTIC results. The findings 
highlight the need for randomised trials assessing the 




The rapid development of medical equipment to help 
physicians in their decision making has led to funda-
mental changes in management of patients throughout 
medical specialties. The implementation of new tech-
niques in clinical practice is often based on the opportu-
nity to assess pathological findings thought to be of 
importance, but randomised clinical trials assessing the 
added value of new techniques on patients’ outcomes 
are often not undertaken before care of patients is 
changed.
The management of rheumatoid arthritis has 
improved greatly over the past decade with the intro-
duction of biologic agents, tight control strategies, and 
early disease modifying anti-rheumatic drug treat-
ment.1-9  With the improvement in rheumatoid arthritis 
care, remission has become an achievable goal for a 
large proportion of patients,10-13  but studies have shown 
WhAT IS AlReAdy knoWn on ThIS TopIC
Clinical remission has become an achievable goal for a large proportion of patients 
with rheumatoid arthritis and is a defined target in treatment recommendations
Several observational studies have shown that inflammation is present in 
rheumatoid arthritis patients who are in clinical remission
Subclinical inflammation as assessed by sensitive imaging modalities is associated 
with structural progression and flare of disease activity
WhAT ThIS STudy AddS
Adding ultrasound information into strategic treatment decisions and targeting 
therapy towards imaging remission (abrogation of inflammation as visualised by 
ultrasound) in rheumatoid arthritis did not lead to improved outcomes
The application of ultrasound imaging remission as a treatment target in rheumatoid 
arthritis may lead to overtreatment and inefficient use of healthcare resources
The ARCTIC study highlights the importance of conducting randomised controlled 
trials to evaluate not only drugs but also new imaging technologies or new 
treatment strategies
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that clinical remission does not necessarily exclude 
progression of joint damage.14 15  An increasing number 
of rheumatologists use ultrasound in the management 
of rheumatic diseases. Ultrasound can assess two 
aspects of synovitis—the morphology and quantity by 
grey scale and synovial vascularity by power Doppler—
and it has been a promising tool for monitoring of dis-
ease activity in rheumatoid arthritis.16-18  Ultrasound 
has been shown to be more sensitive than clinical 
examination in detecting joint inflammation and to 
improve the certainty of a diagnosis of rheumatoid 
arthritis,19-22  and it may also be helpful in procedures 
such as aspiration of joint fluid and intra-articular cor-
ticosteroid injections.23 24  Joint inflammation visualised 
by ultrasound is present in a majority of rheumatoid 
arthritis patients in clinical remission, and several stud-
ies have shown that power Doppler activity is associ-
ated with radiographic progression and disease flare in 
these patients.19 25-30  The potential importance of ultra-
sound in the definition of rheumatoid arthritis remis-
sion and the monitoring of disease activity has led to 
interest in the concept of imaging remission—that is, 
abrogation of inflammation assessed by sensitive imag-
ing techniques.31-35
The ARCTIC (Aiming for Remission in rheumatoid 
arthritis: a randomised trial examining the benefit of 
ultrasound in a Clinical TIght Control regimen) study 
was designed to compare two tight control treatment 
strategies for early rheumatoid arthritis to assess 
whether incorporation of ultrasound information into 
treatment decisions as well as targeting therapy 
towards imaging remission would lead to improvement 
in a combined outcome of sustained clinical remission, 




The ARCTIC trial was a 24 month randomised, open 
label, parallel group clinical strategy study conducted 
at 11 centres in Norway (four rheumatology depart-
ments at university hospitals, six regional/community 
hospitals, and one private practice) in compliance with 
the Declaration of Helsinki and the International Con-
ference on Harmonization Guidelines for Good Clinical 
Practice. The study was conducted and analysed 
according to the protocol and the statistical analysis 
plan (see appendix).
Participants
The main inclusion criteria were age 18-75 years, fulfil-
ment of the 2010 American College of Rheumatology 
(ACR)/European League Against Rheumatism (EULAR) 
classification criteria for rheumatoid arthritis,36 naivety 
to disease modifying anti-rheumatic drugs, time from 
first patient reported swollen joint less than two years, 
and indication for disease modifying drug treatment. 
Patients with abnormal kidney or liver function or 
major comorbidities were excluded (full inclusion and 
exclusion criteria in section 2 of the appendix). All 
patients provided written informed consent.
randomisation and masking
Patients were randomised one to one to either an “ultra-
sound tight control” or a “conventional tight control” 
strategy. The site investigators enrolled patients, and 
randomisation was computer generated with block 
design, concealment of allocation by opaque sequen-
tially numbered sealed envelopes (prepared by a con-
tract research organisation, Smerud Medical Research, 
Oslo, Norway), and stratification for study centre and 
presence of anti-cyclic citrullinated peptide antibodies. 
Investigators and patients were aware of the allocated 
treatment group. The readers of the radiographs were 
masked for clinical information and strategy arm, and 
unblinded study personnel made clinical assessments 
including joint counts.
assessments
Patients were assessed at 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 
16, 20, and 24 months. Patients in the ultrasound 
strategy arm were assessed by ultrasound at every 
visit, according to a scoring system of 32 joints with 
high intra-rater and inter-rater reliability.37  According 
to the scoring system, these 32 joints were scored 
semi-quantitatively as 0-3 for both grey scale and 
power Doppler: metacarpophalangeal joints 1-5, 
radiocarpal joint, intercarpal joint, distal radioulnar 
joint, elbow, knee, talocrural joint, and metatarso-
phalangeal joints 1-5 bilaterally, giving ranges from 0 
to 192 for total ultrasound score and from 0 to 96 for 
grey scale and power Doppler ultrasound scores. The 
ultrasound assessments were performed with Sie-
mens Antares or GE Logiq E9 ultrasound machines 
with linear probes (11.4/13.0 MHz). Power Doppler 
parameters were adjusted according to the device 
used (pulse repetition frequency 391/600 Hz; Doppler 
frequency 7.3/10.0 MHz).38  No changes in ultrasound 
settings were made during the study, and no software 
was upgraded. Patients in the conventional tight con-
trol arm were assessed by ultrasound yearly, but both 
the patient and the treating physician were blinded to 
the results, and the treating physicians did not have 
access privileges to ultrasound data in the electronic 
case report form. In the ultrasound strategy arm, the 
sonographer was also the treating physician, and 
patients were informed of the ultrasound results. All 
the sonographers participating in the study were 
experienced and underwent extensive training with 
both static and dynamic hands-on exercises to cali-
brate readers before the inclusion of the first patient 
and an ultrasound workshop to ensure that calibra-
tion was repeated annually during data collection. 
A  published atlas with ultrasound images showing 
the range of scores of both power Doppler and grey 
scale synovitis in the assessed joints was available at 
all study centres for reference.37  Multicentre training 
and calibration exercises of clinical joint examina-
tions took place before the start of the study and at 
annual investigator meetings during the conduct of 
the study. Examinations were performed according to 
the EULAR handbook of clinical assessments in rheu-
matoid arthritis.39




The ultrasound tight control strategy targeted ultra-
sound imaging remission, defined as no ultrasound 
power Doppler signal in any assessed joint, in combina-
tion with clinical remission, whereas the clinical tight 
control strategy was targeted towards clinical remission 
only. We based the choice of no ultrasound power 
 Doppler signal in any assessed joint as the preferred 
ultrasound treatment target on available literature and 
extensive discussions with clinicians and researchers.29 
Clinical remission was defined as Disease Activity Score 
(DAS) below 1.6 and no swollen joints. DAS (range 0-10, 
higher score indicating more disease activity) is a com-
posite index of four variables: the number of swollen 
joints among 44 examined joints, the Ritchie Articular 
Index with a graded assessment 0-3 of the tenderness in 
26 joint regions, the erythrocyte sedimentation rate, and 
the patient’s global assessment on a visual analogue 
scale ranging from 0 to 100.40  The treatment in both 
arms was escalated according to the same algorithm, 
shown in figure 1  (more details in section 3 of the appen-
dix). The initial treatment was methotrexate 15 mg/week 
increased to 20 mg/week by week five, in combination 
with seven weeks of prednisolone with tapering doses 
from 15 mg to zero. Further steps in the treatment 
 algorithm included methotrexate 25 mg/week, triple 
synthetic disease modifying drug therapy (methotrex-
ate, sulfasalazine, hydroxychloroquine) and biologic 
treatment according to guidelines (fig 1 and appendix 
table S1). In both arms, swollen joints were treated by 
intra-articular steroids; additionally, any joint with 
power Doppler signal in the ultrasound tight control 
arm should be injected. All injections in the ultrasound 
tight control arm were guided by ultrasound.
The clinical decision to adjust therapy was based on 
level of and change in DAS.41 In the ultrasound arm, the 
physician should overrule the DAS based decision and 
proceed to the next treatment regimen if indicated by 
the ultrasound score. We applied a data driven 
approach to derive cut-off values for the ultrasound 
change score in a previously collected dataset using the 
same ultrasound score, by assessing the magnitude of 
changes in ultrasound score corresponding to estab-
lished cut-off values for changes in DAS. The chosen 
cut-off values of 10% and 20% change in ultrasound 
scores corresponded to DAS changes of more than 0.6 
and 1.2, respectively. If the patient did not respond ade-
quately (appendix table S2), the physician immediately 
adjusted the therapy by proceeding to the next step in 
the treatment algorithm. Current therapy was contin-
ued if the treatment response was satisfactory. Study 
personnel entered information on DAS values at the 
current and previous visit, as well as the ultrasound 
score at both visits if applicable, into a web page that 
automatically applied the treatment decisions rules in 
the appropriate study arm (appendix table S2), and the 
treating physician was presented with the outcome of the 
response assessment and whether to escalate treatment.
Outcomes
The predefined primary efficacy endpoint was the 
 proportion of patients meeting the following criteria: 
sustained clinical remission, defined as DAS less than 
1.6 at 16, 20, and 24 months; no swollen joints at 16, 20, 
and 24 months; and no radiographic progression (<0.5 
units change in van der Heijde modified Sharp score) 
between 16 and 24 months.
Radiographs of hands, wrists, and feet were obtained 
at 0, 3, 6, 12, 16, and 24 months. Two trained readers, 
blinded for clinical data and treatment strategy, scored 
radiographs independently in chronological order 
according to the van der Heijde modified Sharp score 
(subscores for erosions (0-280) and joint space narrow-
ing (0-168), total range 0-448, higher scores indicating 
more joint damage). We used the average of the two 
readings for all analyses.
Secondary endpoints included DAS remission, Sim-
plified Disease Activity Index remission (this index 
ranges from 0 to 86, with higher scores indicating more 
disease activity; remission is defined as an index ≤3.3), 
ACR core set outcome variables (assessment of tender 
and swollen joints, pain, patient and investigator 
global  assessment of disease activity, erythrocyte 
 sedimentation rate, and C reactive protein), and fatigue 
visual analogue scale. We assessed physical function by 
the Patient-Reported Outcomes Measurement Informa-
tion 20 item short form (range 20-100, translated to a 
Step 1
DMARD monotherapy
Methotrexate 25 mg/week, increase by 2.5 mg every second week to 20 mg/week
Folic acid 5 mg/week
Prednisolone 15 mg week 1, 10 mg week 2, 7.5 mg week 3, 5 mg week 4 and 5, 2.5 mg week 6 and 7
Step 2
Optimise monotherapy
Methotrexate increase dose to 25-30 mg/week
Step 4
Optimise triple therapy
Prednisolone 7.5 mg x 1 added
Step 5†
First biologic DMARD
Methotrexate and rst TNF inhibitor
Step 7
Further biologic DMARD
Repeat steps 5 and 6 using second biologic therapy and
again with third biologic if failure on second biologic
Step 6
Optimise rst biologic
Methotrexate and rst TNF inhibitor




Sulfasalazine step up over 4 weeks to 1000 mg x 2
Hydroxocloroquine 400 mg x 1
Fig 1 | Protocol for escalation of disease modifying anti-rheumatic (DMarD) treatment. if 
patient responds or reaches target, current treatment is continued. *in patients with high 
disease activity and risk factors for progressive joint destruction, rescue option is 
available which includes moving to step 5 (introduce first biologic). †this step requires 
signs of ongoing inflammatory activity. tnF=tumour necrosis factor
doi: 10.1136/bmj.i4205 | BMJ 2016;354:i4205 | the bmj
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T score with a mean of 50 and a standard deviation of 
10). EuroQol-5 dimensions was assessed with values 
based on UK preference weights with range from 1 (best 
possible health), through 0 (death) to −0.59 (worse than 
death). We included the Rheumatoid Arthritis Impact of 
Disease score, a patient derived weighted score to 
assess seven domains of the impact of rheumatoid 
arthritis (range 0-10, where higher values indicate 
worse status). Additionally, we assessed changes from 
baseline in DAS and van der Heijde modified Sharp 
score, the proportion of patients with radiographic pro-
gression according to different cut-off values, and 
EULAR response rates (details in statistical analysis 
plan in appendix). A complete list of secondary out-
comes is provided in the appendix. We have not 
reported a subset of the pre-specified outcomes, either 
because of feasibility problems or because the method-
ology and interpretation of results would be beyond the 
scope of this paper (magnetic resonance imaging out-
comes, work productivity and activity impairment out-
comes, dual energy x ray absorptiometry outcomes, and 
outcomes from the Medical Outcomes Study Short Form 
36 item). The results of these analyses will be published 
in full in more specialised journals and provided in the 
ClinicalTrials.gov database (NCT01205854). We evalu-
ated safety by assessment of clinical and laboratory 
adverse events and coded serious adverse events 
according to the Medical Dictionary for Regulatory 
Activities ( MedDRA, v17.0).
Patient involvement
No patients were involved in the development of the 
research question or the outcome measures, nor were 
they involved in the design of the study, the recruitment 
of study participants and the conduct of the study. The 
main results from the study will be disseminated to 
study participants in a study newsletter.
statistical analyses
We determined the sample size on the basis of an 
assumed treatment difference of 20% (45% v 65%) in 
the proportion of patients reaching the primary end-
point, yielding 98 patients in each group to reach 80% 
power. We aimed to include 240 patients to compensate 
for attrition. Efficacy and safety analyses included data 
from all randomised patients who started the allocated 
intervention by attending at least one regular visit after 
randomisation (the full analyses set).
We used unadjusted logistic regression to assess the 
primary endpoint and other categorical endpoints. We 
did not adjust the analyses for the stratification factors 
centre and presence of anti-cyclic citrullinated peptide 
antibodies owing to low cell frequencies. If the primary 
endpoint components or other categorical values were 
missing at month 24, we imputed values with worst out-
come. We imputed missing values before month 24 with 
the last known value. We calculated estimates of risk 
difference from the logistic regression parameters by 
using the delta method to provide confidence intervals. 
We used median regression with 10 000 bootstrap repli-
cations to estimate the difference in median radio-
graphic change scores; we used linear intrapolation 
and extrapolation to impute missing values. To analyse 
other continuous change variables, we used analysis of 
covariance adjusted for baseline value in addition to 
study centre and presence of anti-cyclic citrullinated 
peptide antibodies. We used least square means to cal-
culate estimates of treatment difference. We handled 
missing values by using multiple imputations with 10 
imputations drawn from the observed distribution, 
using the Markov chain Monte Carlo method. The statis-
tical significance level was set at 0.05, and all signifi-
cance tests were two sided. Secondary analyses were 
not adjusted for multiple testing. Further statistical 
details are described in the statistical analyses plan and 
appendix section 4. A data monitoring committee was 
not established for this trial. We used Stata Statistical 
Software version 14 for all statistical analyses.
Results
Patient disposition and baseline characteristics
Between 30 September 2010 and 30 April 2013, 238 
patients with early rheumatoid arthritis were included in 
the ARCTIC trial (fig 2 ). One hundred and eighteen 
patients received the allocated ultrasound tight control 
treatment strategy and 112 patients received the conven-
tional tight control strategy and were included in the pri-
mary analysis (fig 2). Of the included patients, 104 
completed the ultrasound tight control arm and 100 com-
pleted the conventional tight control arm. The  frequencies 
and reasons for not receiving allocated treatment strategy 
and for discontinuation during the study were similar in 
the two arms. The two arms were well balanced overall 
with regard to baseline characteristics, but more women 
Allocated to conventional tight control (n=116)Allocated to ultrasound tight control (n=122)
Received allocated strategy (n=112)Received allocated strategy (n=118)
Completed (n=100)Completed (n=104)
Analysed for primary outcome (n=112)Analysed for primary outcome (n=118)
Assessed for eligibility (n=257)
Randomised (n=238)
Randomised, but did not receive
  allocated strategy (n=4):
  Thrombocytopenia (n=1)
  Interstitial lung disease (n=1)
  Withdrew consent (n=1)
  Wrong diagnosis (n=1)
Randomised, but did not receive
  allocated strategy (n=4):
  Did not fulll RA criteria (n=1)
  No indication for DMARD (n=1)
  Withdrew consent (n=1)
  Wrong diagnosis (n=1)
Discontinued (n=14):
  No longer willing (n=2)
  Lost to follow-up (n=2)
  Adverse event (n=6)
  Other (n=3)
  Died (n=1)
Discontinued (n=12):
  No longer willing (n=5)
  Lost to follow-up (n=1)
  Adverse event (n=5)
  Protocol violation (n=1)
Excluded (n=19):
  Did not meet inclusion criteria (n=11)
  Other reasons (n=8)
Fig 2 | trial profile. DMarD=disease modifying anti-rheumatic drug; ra=rheumatoid arthritis
the bmj | BMJ 2016;354:i4205 | doi: 10.1136/bmj.i4205
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were randomised to the ultrasound arm (71% v 51%) 
(table 1). The difference in sex distribution could not be 
attributed to a specific study centre (appendix table S5).
Clinical outcomes
The ultrasound tight control strategy was not superior 
to the conventional tight control strategy with regards 
to the primary outcome (sustained remission, absence 
of radiographic damage, and absence of swollen joints 
between month 16 and 24 of the study). Twenty six 
(22%) patients in the ultrasound tight control group 
and 21 (19%) patients in the conventional tight control 
group reached the primary outcome, with a difference 
between the groups of 3.3% (95% confidence interval 
−7.1 to 13.7; P=0.54) and a risk ratio of 1.18 (95% confi-
dence interval 0.57 to 1.78). We found no difference 
between the groups for any of the three components of 
the primary outcome (table 2).
At 24 months, 68% and 67% of the patients in the two 
arms were in DAS remission (table 2 ). We found no sig-
nificant differences in remission rates at 12 or 24 months 
for either of the remission criteria sets analysed. DAS 
scores, DAS remission rates, Simplified Disease Activity 
Index remission rates, and ACR/EULAR boolean remis-
sion rates were comparable in the two study arms 
during the 24 month study period (fig 3). More than 
80% of patients in both arms showed EULAR good or 
moderate response at 12 months, and this was sus-
tained throughout the study. The patients’ and asses-
sors’ evaluation of the disease activity showed 
substantial improvement compared with baseline, with 
similar results at 12 and 24 months. Patients in both 
groups reported similar levels of improvement in 
 physical function. More patients in the ultrasound tight 
control arm (29%) than in the conventional tight control 
arm (17%) received biologic treatment at the end of the 
study, and fewer patients received methotrexate mono-
therapy (53% v 71%). In the ultrasound tight control 
arm, 167 treatment escalations and 770 intra-articular 
corticosteroid injections occurred, compared with 124 
treatment escalations and 548 intra-articular cortico-
steroid injections in the conventional tight control arm.
radiographic outcomes
The median change in total van der Heijde modified 
Sharp score over 24 months was low, with no statistically 
significant differences between the two strategies. We 
observed a borderline statistically significant  difference 
in the 24 month change in radiographic joint damage 
between the groups, favouring the ultrasound tight con-
trol strategy (table 2 ), and this is visualised in the cumu-
lative probability plot (fig 4 ). The proportion of patients 
with radiographic progression did not differ between the 
two strategy arms (table 2), and we found similar results 
in sensitivity analyses with different cut-off values for 
yearly progression (≥0.5 units, ≥2.0 units, ≥5 units).
sensitivity analyses
In sensitivity analyses, we analysed the primary end-
point, components of the primary endpoint, and the 
table 1 | baseline characteristics. values are means (sDs) unless stated otherwise
Characteristics
ultrasound tight  
control (n=118)
Conventional tight  
control (n=112)
Age, years 50.6 (13.3) 52.3 (14.1)
No (%) women 84 (71) 57 (51)
Body mass index 25.6 (4.4) 26.1 (4.7)
No (%) current smoker 23 (19) 32 (29)
Time since patient reported first swollen joint, months 6.8 (5.2) 7.4 (5.6)
No (%) anti-citrullinated peptide antibody positive 93 (79) 93 (83)
No (%) rheumatoid factor positive 78 (66) 86 (77)
Disease Activity Score 3.51 (1.19) 3.40 (1.16)
Simplified Disease Activity Index 25.5 (12.9) 24.4 (13.3)
Disease Activity Score based on 28 joints 4.42 (1.19) 4.39 (1.20)
Patient’s global assessment of disease activity, mm (0-100) 51.9 (24.7) 47.5 (23.9)
Investigator’s global assessment of disease activity, mm (0-100) 40.9 (20.1) 40.3 (21.2)
Swollen joint count (0-44) 10.9 (7.2) 10.2 (7.8)
Tender joint count (Ritchie Articular Index, 0-78) 9.2 (7.9) 8.4 (6.7)
Erythrocyte sedimentation rate, mm/hr (1-140) 23.2 (18.3) 25.8 (18.9)
C reactive protein, mg/L 14.5 (20.1) 16.6 (22.39
PROMIS Physical Function (12.1-62.5) 38.9 (9.2) 39.2 (8.1)
Median (IQR) EuroQol-5 dimensions (−0.59-1.0) 0.66 (0.16-0.73) 0.66 (0.47-0.73)
Fatigue visual analogue scale, mm (0-100) 43.7 (28.4) 37.0 (28.6)
Pain visual analogue scale, mm (0-100) 48.8 (23.9) 46.8 (24.3)
Median (IQR) van der Heijde modified Sharp score (0-448) 3.8 (1.5-7.5) 5.0 (2.0-10.3)
 Median (IQR) erosion score 2.5 (1.0-4.0) 3.5 (1.5-5.8)
 Median (IQR) joint space narrowing score 1.0 (0.0-3.0) 1.0 (0.0-4.5)
Median (IQR) ultrasound total score (0-192) 24 (16-37) 27 (14-45)
 Median (IQR) ultrasound grey scale score 17 (10-24) 19 (10-31)
 Median (IQR) ultrasound power Doppler 7 (3-13) 7 (2-15)
 No (%) power Doppler signal in any joint 110 (93.2) 97 (86.6)
IQR=interquartile range; PROMIS=Patient-reported Outcomes Measurement Information Score Short Form v1.0 – Physical Function 20a (reported as T scores).
doi: 10.1136/bmj.i4205 | BMJ 2016;354:i4205 | the bmj
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table 2 | Primary and secondary outcomes. values are numbers (percentages) unless stated otherwise
ultrasound tight  
control (n=118)
Conventional tight  
control (n=112) Difference (95% Ci) P value
Primary endpoint
Clinical remission, no swollen joints, and non-progression of radiographic joint damage 26 (22) 21 (19) 3.3 (−7.1 to 13.7) 0.54
Components of primary endpoint
No swollen joints at 16, 20, and 24 months* 62 (53) 61 (54) −1.9 (−14.8 to 11.0) 0.77
Disease Activity Score remission at 16, 20, and 24 months* 64 (54) 58 (52) 2.5 (−10.4 to 15.4) 0.71
No radiographic progression between 16 and 24 months* 49 (42) 39 (35) 6.7 (−5.8 to 19.2) 0.29
Measures of disease activity, physical function, and quality of life
Mean (SD) change in Disease Activity Score:
 At 12 months −2.2 (1.1) −2.1 (1.2) 0.1 (−0.1 to 0.3) 0.26
 At 24 months −2.3 (1.2) −2.0 (1.2) −0.1 (−0.3 to 0.1) 0.49
Disease Activity Score remission (Disease Activity Score <1.6)†:
 At 12 months 76 (64) 81 (72) −7.9 (−19.9 to 4.1) 0.20
 At 24 months 80 (68) 75 (67) 0.8 (−11.3 to 13.0) 0.89
Mean (SD) change in erythrocyte sedimentation rate, mm/hr:
 At 12 months‡ −11.6 (16.5) −14.9 (18.6) 0.9 (−1.2 to 3.1) 0.39
 At 24 months‡ −13.0 (16.8) −13.7 (17.7) −1.1 (-3.3 to 1.0) 0.30
Mean (SD) change in C reactive protein, mg/L:
 At 12 months‡ −10.1 (19.6) −11.7 (21.6) 0 (−1.1 to 1.0) 0.92
 At 24 months‡ −11.0 (19.9) −11.3 (21.9) −1.0 (−2.3 to 0.2) 0.11
Mean (SD) change in investigator’s global assessment:
 At 12 months‡ −34.8 (19.9) −29.9 (21.2) −1.3 (−3.3 to 0.7) 0.19
 At 24 months‡ −33.0 (21.6) −28.0 (23.2) −2.6 (−5.5 to 0.4) 0.09
Mean (SD) change in patient’s global assessment:
 At 12 months‡ −35.1 (25.3) −29.2 (28.8) −1.3 (−6.3 to 3.7) 0.61
 At 24 months‡ −35.9 (25.9) −29.7 (28.1) −0.75 (−6.0 to 4.5) 0.78
Mean (SD) change in Disease Activity Score 28 joints:
 At 12 months‡ −2.4 (1.3) −2.4 (1.4) 0.1 (−0.1 to 0.4) 0.29
 At 24 months‡ −2.5 (1.3) −2.2 (1.3) −0.2 (−0.4 to 0.1) 0.23
Mean (SD) change in Simplified Disease Activity Index:
 At 12 months‡ −21.3 (12.6) −18.9 (12.8) −0.1 (−1.3 to 1.0) 0.83
 At 24 months‡ −20.8 (13.5) −18.3 (13.1) −0.5 (−2.1 to 1.1) 0.56
Simplified Disease Activity Index remission (Simplified Disease Activity Index<3.3)†:
 At 12 months 67 (57) 61 (54) 2.3 (−10.5 to 15.2) 0.72
 At 24 months 71 (60) 56 (50) 10.2 (−2.6 to 23.0) 0.12
ACR-EULAR boolean remission†:
 At 12 months 50 (42) 47 (42) 0.4 (−12.4 to 13.2) 0.95
 At 24 months 57 (48) 55 (49) −0.8 (−12.7 to 12.1) 0.90
EULAR good/moderate response†:
 At 12 months 97 (82) 93 (83) −0.8 (−10.6 to 9.0) 0.87
 At 24 months 98 (83) 90 (80) 2.7 (−7.3 to 12.7) 0.60
No tender joints†‡:
 At 12 months 57 (48) 64 (57) −8.8 (−21.7 to 4.0) 0.18
 At 24 months 67 (57) 60 (54) 3.2 (-9.6 to 16.1) 0.63
No swollen joints†‡:
 At 12 months 87 (74) 78 (70) 4.1 (−7.6 to 15.7) 0.49
 At 24 months 84 (71) 75 (67) 4.2 (−7.7 to 16.2) 0.49
Mean (SD) change in PROMIS Physical Function:
 At 12 months 11.6 (9.1) 11.6 (8.6) −0.3 (−2.4 to 1.8) 0.80
 At 24 months 13.0 (9.5) 11.0 (9.6) 1.28 (−1.1 to 3.6) 0.28
Mean (SD) change in EQ-5D:
 At 12 months‡ 0.28 (0.28) 0.25 (0.29) 0 (−0.05 to 0.05) 0.95
 At 24 months 0.30 (0.28) 0.26 (0.28) −0.01 (−0.06 to 0.05) 0.84
Mean (SD) change in Rheumatoid Arthritis Impact of Disease score:
 At 12 months −2.6 (2.0) −2.4 (2.3) −0.08 (−0.51 to 0.35) 0.71
 At 24 months −2.8 (2.1) −2.5 (2.3) −0.06 (−0.49 to 0.38) 0.79
Mean (SD) change in fatigue visual analogue scale:
 At 12 months‡ −20.0 (31.4) −15.6 (28.5) 1.0 (−4.9 to 6.8) 0.75
 At 24 months‡ −20.8 (32.7) −14.8 (28.7) 1.7 (−4.8 to 8.2) 0.61
(Continued )
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24 month change in radiographic damage with adjust-
ment for sex (appendix table S3), with similar results 
as for the main analysis. We also found similar results 
in analyses of the primary endpoint with imputation 
of best outcome instead of worst outcome (data not 
shown). We also analysed the same variables in the 
completer dataset consisting of 204 patients (appen-
dix table S4). In these analyses, we found a significant 
difference in radiographic damage over 24 months, 
with a difference in change of van der Heijde Sharp 
score of 0.45 units (95% confidence interval −0.86 to 
−0.39; P=0.03) favouring the ultrasound tight control 
group.
adverse events
The overall frequency of adverse events and serious 
adverse events was similar in the two arms (table 3 ). 
Thirteen (6%) patients had serious adverse events, of 
whom five (2%) had serious infections (table 3, appen-
dix table S6). Five cases of cancer were reported: two 
(follicle centre lymphoma, liver metastases) in the 
ultrasound tight control arm and three (basal cell carci-
noma, breast cancer, squamous cell carcinoma) in the 
conventional tight control arm (appendix section 5). 
One patient in the ultrasound tight control arm died 
from Pneumocystis jirovecii pneumonia (appendix 
 section 6).
table 2 | Primary and secondary outcomes. values are numbers (percentages) unless stated otherwise
ultrasound tight  
control (n=118)
Conventional tight  
control (n=112) Difference (95% Ci) P value
Mean (SD) change in pain visual analogue scale:
 At 12 months‡ −32.5 (24.8) −29.2 (28.1) −0.82 (−6.0 to 4.3) 0.75
 At 24 months‡ −31.9 (26.7) −29.1 (25.0) 0.03 (−5.1 to 5.2) 0.99
radiographic joint damage
Median (IQR) changes in modified Sharp score:
 At 12 months 0.5 (0-1.0) 0.5 (0-1.5) −0.28 (−0.60 to 0.04) 0.08
 At 24 months 1.0 (0-2.5) 1.5 (0.5-3.0) −0.45 (−0.90 to 0) 0.05
Median (IQR) change in erosion score:
 At 12 months 0 (0-1.0) 0.5 (0-1.0) −0.35 (−0.70 to 0) 0.05
 At 24 months 0.5 (0-1.5) 1.0 (0.5-2.0) −0.38 (−0.76 to 0.01) 0.06
Median (IQR) change in joint space narrowing score:
 At 12 months 0 (0-0.5) 0 (0-0) 0 (−0.03 to 0.03) >0.99
 At 24 months 0 (0-0.5) 0 (0.0-0.5) 0 (−0.05 to 0.05) >0.99
Progression, modified Sharp score ≥1.0 units/year† 43 (36) 53 (47) −10.9 (−23.6 to 1.8) 0.09
ultrasound outcomes
Mean (SD) change in ultrasound total score:
 At 12 months −25.0 (18.3) −23.7 (23.4) −3.7 (−5.8 to -1.7) <0.001
 At 24 months −25.5 (18.3) −26.7 (26.1) −2.2 (−4.0 to -0.42) 0.02
Mean (SD) change in ultrasound grey scale score:
 At 12 months −15.9 (11.6) −15.0 (13.9) −2.7 (−4.3 to -1.2) 0.001
 At 24 months −16.5 (11.6) −17.1 (15.6) −1.6 (−2.9 to -0.28) 0.02
Mean (SD) change in ultrasound power Doppler:
 At 12 months -9.2 (8.2) −8.8 (10.5) −1.0 (−1.7 to -0.29) 0.007
 At 24 months -9.0 (8.1) −9.6 (11.5) −0.61 (−1.3 to 0.04) 0.06
No power Doppler signal in any joint†:
 At 12 months 94 (80) 60 (54) 26.1 (14.3 to 37.8) <0.001
 At 24 months 89 (75) 69 (62) 13.8 (1.9 to 25.7) 0.02
Drug treatment‡
Disease modifying anti-rheumatic drug regimen at 24 months:
 Methotrexate monotherapy 63 (53) 80 (71) −18.0 (−30.3 to -5.8) 0.004
 Methotrexate/sulfasalazine/hydroxychloroquine combination 21 (18) 13 (12) 6.2 (−2.9 to 15.3) 0.18
 Biologic treatment 34 (29) 19 (17) 11.8 (1.1 to 22.6) 0.03
  First biologic 27 (23) 10 (9) 14.0 (4.7 to 23.2) 0.003
  Second biologic 5 (4) 9 (8) −3.8 (v10.0 to 2.4) 0.23
  Third biologic 2 (2) 0 (0) NE 0.50
Mean (SD) methotrexate dose at 24 months, mg 20.4 (5.0) 21.1 (4.5) −0.7 (−2.1 to 0.6) 0.28
Median (IQR) total prednisolone dose, mg§ 570 (420-890) 634 (468-844) −2.5 (−71.5 to 66.5) 0.94
Any NSAID use over 24 months 55 (47) 52 (46) 0 (−0.12 to 0.13) 0.98
Any intra-articular injections 103 (87) 86 (77) 10.5 (0.6 to 20.4) 0.04
Mean (SD) No of intra-articular injections 6.5 (6.0) 4.9 (5.9) 1.7 (0.2 to 3.2) 0.03
Mean (SD) total triamcinolone hexacetonide dose, mg§ 94 (88) 69 (129) 25 (−4 to 54) 0.09
ACR=American College of Rheumatology; EQ-5D=EuroQol-5 dimensions; EULAR=European League Against Rheumatism; NE=not estimable (P value based on Fischer’s exact test for third 
biologic); NSAID=non-steroidal anti-inflammatory drug; PROMIS=Patient-reported Outcomes Measurement Information Score Short Form v1.0 – Physical Function 20a (reported as T scores).
*Missing data before 24 months imputed using last observation carried forward; missing data at 24 months imputed using worst outcome.
†Missing data were imputed using worst outcome imputation.
‡Outcomes not listed in the ClinicalTrials.gov registry on 20 September 2010 (before patient enrolment), but described in trial protocol and/or statistical analyses plan before database lock and 
analyses (see appendix).
§Cumulative dose per patient.




In this study, we assessed the benefit of adding ultra-
sound information to the treatment decisions and 
treatment target in early rheumatoid arthritis. The 
study was designed on the basis of the increasing 
application of ultrasound in clinical practice, as well 
as several studies showing that ultrasound examina-
tions improve assessment of synovitis and prediction 
of important patient outcomes.19 Our study found no 
additional effect of an ultrasound tight control strat-
egy compared with a conventional tight control strat-
egy for the  primary outcome of the study or for other 
measures of disease activity, joint damage, and physi-
cal function.
strengths and limitations of study
The study has limitations as well as strengths. This was 
an open study, and two components of the primary end-
point, the tender and swollen joint counts, were not 
blinded. This leaves a potential for bias in treatment 
decisions based on these parameters. Although remis-
sion rates were excellent, fewer patients than expected 
in the power calculations reached the strict composite 
primary outcome. In our sample size estimations, we 
aimed for 80% power to detect a 20% difference 
between the interventions (see protocol). If the study 
was to be repeated, the power to detect a 20% difference 
in the primary endpoint from 19% in the control group 
would have been 89%, showing that the completed trial 
was not underpowered to detect a clinically important 
difference. This can also be deduced from the results 
presented in this manuscript. The estimated treatment 
difference of the primary endpoint was 3.3% with a 95% 
confidence interval of −7.1 to 13.7. The confidence limits 
of the primary efficacy outcome are completely within 
the ±20% margin, excluding a clinically significant 
effect of the intervention (appendix section 7). Sensitiv-
ity analyses in the completer population and analyses 
in the full analyses set with imputation of best outcome 
instead of worst outcome resulted in similar results, 
supporting our conclusion. A pilot study showed good 
intra-reader and inter-reader reliability for the 
 ultrasound scoring system,37  but no consensus has 
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Conventional tight control strategy
Ultrasound tight control strategy
Fig 3 | top left: Disease activity score (Das) over 24 months; least square mean estimates of Das at all visits derived from 
mixed effects longitudinal model adjusted for baseline value and stratification factors. top right: proportion of patients who 
achieved Das remission over 24 months derived from logistic regression model. bottom left: proportion of patients who 
achieved simplified Disease activity index (sDai) remission over 24 months derived from logistic regression model. bottom 
right: proportion of patients who achieved american College of rheumatology (aCr)/european league against rheumatism 
(eular) boolean remission over 24 months from logistic regression model. bars indicate 95% confidence limits






















Conventional tight control strategy
Ultrasound tight control strategy
Fig 4 | Cumulative probability plot of change between baseline 
and 24 months in van der Heijde modified sharp score
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sound in rheumatoid arthritis.18  Our findings are 
strengthened by both strategies adhering to interna-
tional recommendations,10 13  and by the fact that the 
primary endpoint comprised sustained clinical remis-
sion and halt of radiographic progression, thus captur-
ing the most important aspects of rheumatoid arthritis.4 
Two trained and blinded readers at a central facility 
read radiographs with known chronological order, to 
optimise sensitivity to change.42 The inclusion criteria 
stated that the patients should have a clinical indica-
tion for disease modifying anti-rheumatic drug therapy, 
as well as a diagnosis of rheumatoid arthritis and fulfil-
ment of the 2010 ACR/EULAR classification criteria. We 
imposed no formal entry criteria regarding the level of 
DAS. At baseline, the mean DAS was in the upper range 
of moderate. We aimed to include a study population 
capturing a broad range of rheumatoid arthritis disease 
activity, not a subset with high disease activity, as is 
often the case in studies of new drugs. We believe this 
heterogeneity to be a strength of the study, as it reflects 
real life practice.
Comparison with other studies
The introduction of biologic therapies in combination 
with aggressive treatment strategies has led to levels of 
disease control previously thought impossible in rheu-
matoid arthritis, and remission has become a realistic 
goal of therapy.3 4 9-13 15  Remission rates in both study 
arms of this trial were excellent compared with other 
trials of strategy in early rheumatoid arthritis, with min-
imal radiographic progression.1 43-46  Our results show-
case the power of a treatment approach targeting deep 
clinical remission, follow-up with tight control, and 
starting treatment with methotrexate and predniso-
lone, combined with intra-articular injections in swol-
len joints. After 24 months, more than 70% of patients 
in the conventional arm were still on methotrexate 
monotherapy and only 17% needed a biologic agent. In 
an ideal setting, remission in rheumatoid arthritis 
should represent absence of inflammation and no pro-
gression of joint damage, but current clinical remission 
criteria do not include imaging assessments. A key 
question has been whether treatment of subclinical 
inflammation would improve long term outcomes or 
whether this will lead to overtreatment.19 31 32 35  We are 
aware of one other trial (NCT00920478) designed to 
assess the value of ultrasound in rheumatoid arthritis. 
The clinical target of that study was low disease activity 
and not remission, which is the preferred target in cur-
rent treatment recommendations.11 13  Results from this 
trial indicate similar clinical and radiographic out-
comes in both study arms.47
Possible explanations and implications for clinicians
The outcome of the study is to a certain degree surpris-
ing, in that a growing body of evidence suggested that 
subclinical inflammation, especially power Doppler 
activity, was associated with radiographic progression 
and flares.19 25 26 28 29 31  However, a recent study showed 
that radiographic progression was rare in joints with 
subclinical inflammation.48  The ultrasound strategy 
led to additional changes in disease modifying drug 
therapy, with fewer patients remaining on methotrexate 
monotherapy and more patients receiving biologic 
treatment, as well as a higher number of intra-articular 
corticosteroid injections. Adherence of patients and 
physicians to a pre-specified treatment protocol target-
ing remission can be challenging, and in several clini-
cal situations rheumatologists may be reluctant to base 
treatment decisions solely on an algorithm rather than 
integrating all available information. A recent report 
from the BeST study evaluated rheumatologists’ adher-
ence to a treat to target strategy steered by DAS, and 
average protocol adherence was 79%.49 In our trial, we 
found that 19% of treatment changes deviated from the 
decision rules of the treatment algorithm. The result of 
each ultrasound joint assessment in the ultrasound 
tight control arm was communicated to the patient, and 
despite the extra time and effort required, most patients 
appreciated the opportunity to directly observe the 
level of inflammation inside the joints. This may con-
tribute to increased adherence of patients to therapy, in 
that ongoing inflammation would improve patients’ 
motivation to escalate treatment and resolution of 
inflammation might reassure the patient that the cur-
rent therapy was effective.
Despite the more aggressive treatment in the ultra-
sound tight control group, inflammation assessed by 
ultrasound was significantly suppressed in both study 
arms, with most patients having no power Doppler 
activity in any joint after two years (appendix figure S1). 
A possible explanation may be that isolated subclinical 
inflammation in the absence of clinically detectable dis-
ease activity has minimal clinical importance, making 
direct visualisation of power Doppler activity unneces-
sary. We found a trend towards a difference in progres-
sion of joint damage, and we do not know whether a 
longer follow-up period would have shown a benefit of 
the ultrasound strategy. However, only a very subtle dif-
ference existed in the total modified Sharp score in the 
progression between the groups. In a study of patients 
with early rheumatoid arthritis who were followed over 
10 years, a longitudinal association between total mod-
ified Sharp scores and functional outcome assessed by 
Health Assessment Questionnaire was found, and an 
increase of 10 units in the radiographic score was asso-
ciated with a 0.03 unit increase (worsening) in Health 






Adverse events 417 455
Patients with adverse events 96 (81) 91 (81)
Patients with serious adverse events 6 (5) 7 (6)
Patients with serious infection 3 (3)* 2 (2)†
Discontinuation from study due to adverse event 7 (6) 5 (4)
Patients with cancer 2 (2)‡ 3 (3)§
Death 1 (1)¶ 0
*Pneumocystis jirovecii pneumonia, pneumonia, and bacterial abscess.
†Abscess and localised infection.
‡Follicle centre lymphoma and metastases to liver.
§Basal cell carcinoma, breast cancer, and squamous cell carcinoma.
¶Patient died from Pneumocystis jirovecii pneumonia.
doi: 10.1136/bmj.i4205 | BMJ 2016;354:i4205 | the bmj
RESEARCH
10
Assessment Questionnaire score, which has a total 
range of 0-3 units.50  Thus, the observed difference of 
0.45 modified Sharp score units over 24 months in our 
study is not clinically meaningful. The difference is 
present only in the erosion score and not in the joint 
space narrowing score, which has been found to be 
more strongly associated with irreversible loss of func-
tion than is erosive damage.51  The observed trend in the 
erosive score may be due to more frequent initiation of 
biologic drugs in the ultrasound tight control group, 
which is known to inhibit radiographic progression 
independently of disease activity.4
implications for policy makers
New drugs commonly undergo health economic evalua-
tions before they are funded through national healthcare 
systems or private medical insurance, whereas such 
 evaluations are less strictly imposed for new imaging 
modalities and other medical techniques before imple-
mentation into clinical care. Although we did not aim to 
analyse cost effectiveness data, the lack of gain in bene-
fits and the increased costs, time consumption, and use 
of biologic drugs associated with the ultrasound tight 
control regimen would yield negative cost-benefit ratios.
Conclusions and future research
The ARCTIC study highlights the importance of conduct-
ing randomised controlled trials to evaluate not only 
drugs but also new technologies or new treatment strat-
egies. The implementation and systematic use of ultra-
sound in the follow-up of patients with early rheumatoid 
arthritis treated with an aggressive tight control strategy 
is not justified on basis of the results of the ARCTIC trial, 
and the result should be reflected in future recommen-
dations and guidelines for managing patients with rheu-
matoid arthritis. Ultrasound may have an important role 
in the diagnosis of rheumatoid arthritis and in proce-
dures such as intra-articular injections. Future studies 
should focus on the potential benefit of ultrasound in 
these areas, as well as the possible role of ultrasound 
in evaluating disease activity and tailoring treatment in 
patients with established rheumatoid arthritis.
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